Gentile S^1,2, Guarino G¹, Della Corte T^1,2, Satta E^2-4, Pipicelli AMV⁵, Romano C², Alfarone C², Lamberti R⁶, Di Maio A⁶ and Strollo F⁷*

¹Campania University “Luigi Vanvitelli”, Naples, Italy
²Nefrocenter Research and Nyx Start-UP, Naples, Italy
³Haemodialysis Center s.r.l. Nefrocenter Network, Naples, Italy
⁴Polyspecialist Nephrology Center CNP Srl, Nefrocenter Network SRL, Frattamaggiore, Italy
⁵Nephrology, Dialysis and Transplant Unit, Medical and Surgical Science Department, “A. Gemelli” University Polyclinic IRCCS Foundation, Catholic University of the Sacred Heart, Rome, Italy
⁵Metelliano Medical Center, Nefrocenter Network, Naples, Italy
⁶IRCCS San Raffaele Pisana, Rome, Italy

*Corresponding Author: Strollo F, IRCCS San Raffaele Pisana, Rome, Italy.

Received: August 21, 2021; Published: December 27, 2021

Abstract

Background: patients with type 2 diabetes mellitus (T2DM) often discontinue Sodium-Glucose Cotransporter-2-inhibitors (SGLT2-Is) despite high efficacy and safety due to genital infection (GI).

Aim of the study: to assess real-life GI risk profile in post-menopausal T2DM patients educated on strict hygiene-based prevention practices (SHBPPs) due to their intrinsic GI susceptibility.

Methods: 721 post-menopausal T2DM patients willing to follow SHBPPs were randomly assigned to three different SGLT2-Is (intervention group, IG, n=318) or other drugs (control group, CG, n=403) for three- months. Before and after treatment, they underwent routine lab tests and completed a specific questionnaire.

Results: GIs more often occurred (9.6 %; p < 0.001) among IG women non-adhering to SHBPPs (41.5%) vs. the 2.9% of adhering ones. Conversely CG women had superimposable GI rates (2.7% vs. 3.1%, respectively, p n.s.) whether or not adhering to SHBPPs (51.4 vs. 49.6%, respectively, p n.s.). The typical profile of women on SGLT2-Is at higher risk for GIs included (i) poor adherence to SHBPPs, (ii) older age, (iii) higher BMI, (iv) poor glucose control as witnessed by high HbA1c levels, and (v) antihypertensive drug utilization.

Conclusion: physicians should consider the importance of strict hygiene control in their post-menopausal T2DM patients undergoing SGLT2-I treatment and thus utilize better-focused education strategies in that specific subgroup to prevent or rehabilitate from repeated GIs.

Keywords: Type 2 Diabetes; SGLT2-Inhibitors; Genital Infections; Menopause; Prevention; Rehabilitation

References

1. Hasan FM., et al. “SGLT2 inhibitors in the treatment of type 2 diabetes”. Diabetes Research and Clinical Practice3 (2014): 297-322.
2. Dardi I., et al. “SGLT2 inhibitors”. Biochemistry and Pharmacology 101 (2016): 27-39.
3. Zaccardi F., et al. “Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis”. Diabetes, Obesity and Metabolism8 (2016): 783-794.
4. Vasilakou D., et al. “Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis”. Annals of Internal Medicine4 (2013): 262-274.
5. S. Food and Drug Administration. “FDA approves Forxiga to treat type 2 diabetes 2014 [FDA NEWS RELEASE]” (2014).
6. S. Food and Drug Administration. “FDA approves Invokana to treat type 2 diabetes 2013 [FDA NEWS RELEASE]” (2013).
7. S. Food and Drug Administration.” FDA approves Jardiance to treat type 2 diabetes 2014 [FDA News Release]” (2014).
8. European Medicines Agency. “Forxiga (dapagliflozin): EPAR summary for the public”. 2012EMEA/H/C/002322 (2019).
9. European Medicines Agency. “Invokana (canagliflozin): EPAR summary for the public”. 2013EMEA/H/C/002649 (2019).
10. European Medicines Agency. “Jardiance (empagliflozin): EPAR summary for the public”. 2014 EMEA/H/C/002677 (2019).
11. Markham A and Elkinson S. “Luseogliflozin: first global approval”. Drugs 74 (2014): 945-950.
12. Poole RM and Dungo RT. “Ipragliflozin: first global approval”. Drugs 74 (2014): 611-617.
13. Poole RM and Prossler JE. “Tofogliflozin: first global approval”. Drugs 74 (2014): 939-944.
14. Kotsis V., et al. “Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient”. Journal of Hypertens3 (2020): 377-386.
15. Benfield T., et al. “Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome”. Diabetologia 50 (2007): 549-554.
16. Geerlings S., et al. “Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria”. Diabetes Research and Clinical Practice3 (2014): 373-381.
17. Geerlings S., et al. “Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria”. Diabetes Research and Clinical Practice 103 (2014): 373-381.
18. S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections (2015).
19. Kawalec P., et al. “The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis”. Diabetes/Metabolism Research and Reviews 4 (2014): 269-283.
20. Wu JH., et al. “Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis”. Lancet Diabetes Endocrinology 5 (2016): 411-419.
21. Liu J., et al. “Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis”. Scientific Report1 (2017): 2824.
22. Beigi RH., et al. “Vaginal yeast colonization in non-pregnant women: a longitudinal study”. Obstetrics and Gynecology 104 (2004): 926‐930.
23. Centers for Disease Control and prevention. “Atlanta, Centers for Disease Control and Prevention (CDC)” (2015).
24. Achkar JM and Fries BC. “Candida infections of the genitourinary tract”. Clinical Microbiology Review2 (2010): 253‐273.
25. Ramsay S., et al. “Practical management of recurrent vulvovaginal candidiasis”. Trends in Urology, Gynaecology and Sexual Health 14 (2019): 18‐22.
26. Gunther LSA., et al. “Prevalence of Candida albicans and non‐albicans isolates from vaginal secretions: comparative evaluation of colonization, vaginal candidiasis and recurrent vaginal candidiasis in diabetic and non‐diabetic women”. Sao Paulo Medical Journal2 (2011): 116‐120.
27. Bagnall P and Rizzolo D. “Bacterial vaginosis: A practical review”. JAAPA12 (2017): 15-21.
28. Gruppo di studio ANNALI AMD. “Gli Annali AMD: un modello di monitoraggio sistematico e miglioramento continuo della qualità dell'assistenza diabetologica [AMD Annals: a model of continuous monitoring and improvement of the quality of diabetes care]”. Epidemiologia e Prevenzione 1 (2011): 18-26.
29. U. Serie Generale n.234 del 05-10-2019. Update of the AIFA therapeutic plan for the prescription from the National Health Service for the appropriate use of sodium-glucose 2 (SGLT-2) co-transporter inhibitor drugs (SGLT-2) and their pre-established associations in type 2 diabetes. (Determina n. DG/1368/2019). (19A06126).
30. National Center for Health Statistics. International Classification of Diseases, Tenth Revision (ICD-10).
31. American Diabetes Association. “9 Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020”. Diabetes Care 43 (2020): S98-S110.
32. Manicardi V., et al. “Recommendations for the prevention of urogenital infections in women with diabetes: The decalogue of prevention”. AMD Gender Medicine Study Group (Associazione MediciDiabetologi) (2016).
33. Sample size calculator for estimating a single proportion. Sydney (2021).
34. Mahaffey KW., et al. “Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups”. Circulation9 (2019): 739-750.
35. Perkovic V., et al. “Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy”. The New England Journal of Medicine 24 (2019): 2295-2306.
36. Boyko EJ., et al. “Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women”. American Journal of Epidemiology6 (2005): 557-564.
37. Stamm WE and Raz R. “Factors contributing to susceptibility of postmenopausal women to recurrent urinary tract infections”. Clinical Infectious Diseases 4 (1999): 723-725.
38. Unnikrishnan AG., et al. “Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus”. Indian Journal of Endocrinology and Metabolism 6 (2018): 837-842.
39. Aggarwal A., et al. “High Prevalence of Genital Mycotic Infections with Sodium-glucose Co-transporter 2 Inhibitors among Indian Patients with Type 2 Diabetes”. Indian Journal of Endocrinology and Metabolism 1 (2019): 9-13.
40. Nyirjesy P., et al. “Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies”. Current Medical Research and Opinion 6 (2014): 1109-1119.
41. Unemo M., et al. “Sexually transmitted infections: challenges ahead”. Lancet Infectious Diseases8 (2017): e235-e279.
42. North American Menopause Society. “Menopause Practice: A Clinician’s Guide, 4rd ed. The North American Menopause Society”. Canadian Family Physician9 (2012): 989.
43. Crichton J., et al. “Socioeconomic factors and other sources of variation in the prevalence of genital chlamydia infections: A systematic review and meta-analysis”. BMC Public Health 15 (2015): 729.
44. Shrestha A., et al. “Analysis of socio-demographic and microbiological profile of vaginal discharge in patients attending Kathmandu University Hospital, Nepal”. Bangladesh Journal of Medical Science4 (2015).
45. Mohan V., et al. “Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment”. Diabetes Therapy1 (2020): 15-35.
46. Wilkinson D., et al. “Family planning services in developing countries: an opportunity to treat asymptomatic and unrecognised genital tract infections?” Genitourinary Medicine6 (1997): 558-560.
47. Bourrel P. “Complications des coutumes et mutilations rituelles chez l'Africain [Problems related to African customs and ritual mutilations]”. Contraception, Fertilité, Sexualité (Paris)12 (1983): 1351-1358.

Citation

Citation: Strollo F., et al. “Genital Infection Risk Profile in Post-menopausal Women with Type 2 Diabetes Mellitus on Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors”.Acta Scientific Medical Sciences 6.1 (2022): 292-313.

Copyright

Copyright: © 2022 Strollo F., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.